Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05241834 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05241834 · ClinicalTrials.gov record · last posted 2026-08-21

A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment

StatusCompleted
PhasePhase 1
Started2022-03-23
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-260. LOXO-260 may be used to treat cancer that has a change in a particular gene (known as the RET gene). Participation could last up to 24 months (2 years) and possibly longer if the disease does not get worse.

Protocol amendment history 1 change detected by DataLookout

2026-08-22
Trial completed
Trial Details
NCT Number NCT05241834
Lead Sponsor Eli Lilly and Company
Conditions Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms
Enrollment 70 participants
Start Date 2022-03-23
Primary Completion 2024-09-17 (estimated)
Study Completion 2026-06-03 (estimated)
Updated on ClinicalTrials.gov 2026-08-21